mate studies of pox and DNA-based immunogens in simianhuman immunodeficiency virus models have shown reduced peak and set-point levels of viremia after experimental challenge [2] but also have demonstrated viral escape from vaccine-induced epitope-specific cytotoxic T lymphocytes (CTLs) [3, 4] , underscoring the need for long-term follow-up.
Thus far, observations of human subjects who became infected with HIV-1 were from clinical trials of recombinant envelope subunit vaccines, not live vector-based immunogens. Recombinant gp120 subunit vaccines were found to not significantly influence early HIV infection [5, 6] , although another report analyzing many of the same study participants suggested that gp120 vaccine-induced antibody responses influenced the genetic spectrum of infecting strains [7] .
The HIV Vaccine Trials Network (HVTN), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), has completed safety and immunogenicity trials of several canarypox vector (ALVAC) HIV-1 vaccines constructed with clade B sequences. These candidate vaccines had excellent safety profiles [8] , and, since clade B/E constructs are being tested in an efficacy trial in Thailand, it is useful to review the course of individuals who became infected with HIV while enrolled in safety and immunogenicity trials of ALVAC HIV-1 vaccines. We summarize the natural history of early HIV-1 infection among participants who received an ALVAC HIV-1 vaccine with or without a booster dose of recombinant gp120 or gp160, compared with that among placebo recipients.
Methods. Participants acquired HIV-1 infection while enrolled in 1 of 5 double-blinded, randomized canarypox HIV-1 vaccine prime-boost trials conducted at US vaccine trial sites in the HVTN, AIDS Vaccine Evaluation Group (AVEG), or HIV Network for Prevention Trials (HIVNET). Phase 1 and 2 trials of canarypox vectors expressing envelope, gag, and protease genes (AVEG 012A/B, AVEG 022A, AVEG 202/HIVNET 014, and AVEG 034/034A) have been described elsewhere [1, [9] [10] [11] . For completeness, HIV-1 incidence is presented across all canarypox HIV-1 vaccine prime-boost trials; 4 additional phase 1 canarypox HIV-1 vaccine prime-boost trials, in which no participants acquired HIV-1 infection (AVEG protocols 022, 026, 029, and 032), were included in the calculation of incidence rates and follow-up in person-years. The numbers of infections are too few to assess efficacy.
To evaluate immunologic and virologic parameters of vaccinees or placebo recipients who became infected with HIV while enrolled in HIVNET, AVEG, or HVTN phase 1 and 2 trials, participants who acquired HIV were asked to participate in a breakthrough-infection protocol (HIVNET 014A, AVEG 402, and HVTN 403, respectively). These protocols were approved by the respective networks, NIAID Division of AIDS, and institutional review boards of participating HIV vaccine trial units. All participants provided written, informed consent. Antiretroviral therapy (ART) was not provided directly through these protocols; initiation of ART was decided by participants and their providers, and referrals were provided.
HIV-1 infection was confirmed on the basis of a diagnostic algorithm that included HIV-1 serologic testing, DNA polymerase chain reaction (PCR), and reverse-transcriptase PCR (RT-PCR). Participants who did not enroll in a breakthroughinfection protocol but had HIV RNA level (virus load) determination and CD4 cell count testing performed through the parent vaccine protocol were included. Participants were interviewed by use of standardized questionnaires, to determine exposure history and clinical symptoms between the last HIVnegative and the first HIV-positive test result visit. Time of infection was estimated by use of an algorithm based on the participant's last negative and first positive Western blot or PCR result, acute retroviral symptoms, and exposure history [5] . When participants did not report exposure or seroconversion symptoms, the date was assigned as the midpoint between the last negative and the first positive Western blot or PCR result for which the date assigned was not !1 month before the first positive result.
Baseline and quarterly assessment of participants included history and clinical examination, CD4 and CD8 T lymphocyte subsets, and quantitative plasma HIV RT-PCR (Roche Amplicor), with the standard limit of detection of 400 copies/mL. Samples with !400 copies/mL were tested by use of the ultrasensitive assay (limit of detection, 50 copies/mL) and DNA PCR of peripheral blood mononuclear cells (PBMCs). All available plasma virus loads and CD4 cell counts between 1996 and 2002 were included in the analysis.
Time-dependent measurements of plasma virus load, CD4 cell counts, and initiation of ART were compared between groups by use of Kaplan-Meier survival curves and the logrank test. We used the US Public Health Services guidelines to define a composite end point [12] reflecting current guidelines for initiation of ART, which includes plasma virus load 155,000 copies/mL and CD4 cell count !350 cells/mm 3 . The proportion reporting symptomatic seroconversion was assessed by use of Fisher's exact test. Nonparametric analysis by use of the Wilcoxon rank sum test was used to assess differences in pretreatment plasma virus loads and CD4 cell counts, given temporal changes in treatment guidelines. A loess curve was generated to summarize longitudinal pre-ART virus loads of vaccinees. SAS (version 8.2; SAS Institute) and S-PLUS (version 6.0; Insightful) were used for all analyses.
Results. A total of 1497 study participants enrolled in 9 phase 1 and 2 phase 2 canarypox HIV-1 vaccine prime-boost trials, of whom 1257 were vaccinees (follow-up, 3580.7 personyears) and 240 were placebo recipients (follow-up, 596.1 person-years). Overall, 30 participants (2%) acquired HIV-1 infection after enrollment, of whom 18 consented to enroll in breakthrough-infection protocols. Two participants seroconverted between screening and first vaccination and were excluded because they became infected with HIV before a possible vaccineinduced immune response, resulting in an HIV-1 incidence of 1.9%. Data from 12 individuals who did not enroll in breakthrough-infection protocols were included, for whom determination of virus loads and CD4 cell counts were performed at the first HIV-positive visit, through the vaccine protocol. Thus, we summarize data from 28 individuals (21 vaccinees [follow-up, 34. Most breakthrough infections occurred among participants enrolled in phase 2 canarypox HIV-1 vaccine prime-boost trials-16 in AVEG 202/HIVNET 014 and 6 in HVTN 203-and the remainder in phase 1 trials. Almost all subjects ( ) n p 26 were enrolled in trials of vCP205 or vCP1452 containing gag, pol, and env constructs. Of the 28 individuals with breakthrough infection, before HIV-1 infection, 19 vaccinees and 7 placebo recipients received у3 vaccinations, and 2 vaccinees received р2 vaccinations (table 1) . Fourteen participants received a canarypox HIV-1 vaccine with a booster dose of gp120 or gp160, and 7 received the canarypox vaccine and a booster dose of placebo. Despite the provision of counseling at each visit, most participants acquired HIV-1 through sexual exposure (table 1) .
HIV-1 incidence rates among individuals reporting high-risk activities at enrollment were 1.50 HIV infections/100 personyears (95% confidence interval [CI], 0.87-2.4 HIV infections/ 100 person-years) for vaccinees and 1.31 HIV infections/100 person-years (95% CI, 0.48-2.85 HIV infections/100 personyears) for placebo recipients. For those reporting low-risk activities at enrollment, incidence rates were 0.16 HIV infections/100 person-years (95% CI, 0.04-0.42 HIV infections/100 person- years) for vaccinees and 0.73 HIV infections/100 person-years (95% CI, 0.02-4.06 HIV infections/100 person-years) for placebo recipients. Because of small sample sizes and overlapping CIs, no conclusions can be made about the efficacy of these vaccines in reducing acquisition of HIV-1. Overall, the clinical and virologic course of early infection was similar between vaccinees and placebo recipients with breakthrough infections. Eleven vaccinees (52.4%) and 2 placebo recipients (28.6%) retrospectively reported symptoms consistent with an acute retroviral syndrome (table 1; ). Virus load P p .4 and CD4 cell counts were censored at 18 months, since the longest follow-up of placebo recipients was 13 months. The median (25th-75th percentile) of subject-specific medians of pretreatment plasma virus load (vaccinees, 4.78 log 10 copies/mL [3.67-5.29 log 10 copies/mL]; placebo recipients, 4.27 log 10 copies/ mL [3.35-4 ]) were not statistically significant ( and , respectively, Wilcoxon rank P p .4 P p .1 sum test). The duration of follow-up ranged from 1 month to 4 years (infected participants were identified between 1996 and 2002), but there was no difference in calendar year of HIV-1 infection between vaccinees and placebo recipients ( , Wil-P p .7 coxon rank sum test). However, the time until initiation of ART was somewhat longer for vaccinees than for placebo recipients who became infected with HIV (15.2 vs. 4.4 months; , P p .18 log-rank test).
The time from estimated date of HIV-1 infection to the composite end point (plasma virus load 155,000 copies/mL, CD4 cell count !350 cells/mm 3 , or initiation of ART) was not different between vaccinees and placebo recipients (upper bound of the 95% CI for the hazard ratio between vaccinees and placebo recipients, 2.28;
, log-rank test). Of those included in the P p .67 composite-end-point analysis, 12 of 21 vaccinees and 5 of 7 placebo recipients reached the composite end point; 9 vaccinees and 2 placebo recipients were censored because of not reaching the composite end point during follow-up.
Longitudinal virus load before initiation of ART, among the vaccinees with breakthrough infections, is represented in figure  1 , which indicates heterogeneity in early virus load similar to that among untreated historical control subjects [13] [14] [15] . One vaccinee, 014A-8, who received 4 immunizations of vCP205 alone, demonstrated an atypical course after infection, with low virus load (!50 copies/mL, except for a single value of 762 copies/mL plasma HIV-1 RNA at the same visit at which DNA PCR was also positive in PBMCs) and CD4 cell count 1500 cells/mm 3 for 4 years without receiving ART. This participant is currently under intensive study to assess whether his viral suppression and sustained high CD4 cell count may be related to acquisition of a virus of low virulence or characteristics of his HIV-specific CTL response before or after infection.
Discussion.
We summarize 28 participants enrolled in phase 1 and 2 canarypox HIV-1 vaccine prime-boost trials who became infected with HIV through high-risk behavior, despite risk-reduction counseling. HIV-1 seroincidence rates among canarypox HIV-1 vaccinees and placebo recipients were similar and comparable to those in the HIVNET Vaccine Preparedness Study (1.38 HIV infections/100 person-years) [16] . However, for these canarypox HIV-1 vaccines, reliable estimates of efficacy in reducing HIV-1 acquisition cannot be derived, given the small sample size of phase 1 and 2 trials and the differences in immunogens and immunization schedules across protocols.
Vaccinees and placebo recipients who became infected with HIV were not different, with respect to the proportion with symptomatic seroconversion and rate of disease progression, and were similar to previous natural-history cohorts. Because of the semiannual HIV-1 testing and the time to enrollment in breakthrough-infection protocols, peak viremia was not captured. As this will likely be the case in phase 3 efficacy trials, a clinically relevant composite end point encompassing viral set point, decrease in CD4 cell count, and time to initiation of ART has been proposed, to compare postinfection clinical natural history between vaccinees and placebo recipients [12] .
The time to plasma virus load of 55,000 copies/mL, CD4 cell count !350 cells/mL, and initiation of ART was similar among vaccinees and placebo recipients who became infected with HIV, although the present study had limited power to detect differences. With the variability in virus load and CD4 cell counts in recently infected persons [13] [14] [15] , a larger number of breakthrough infections and placebo recipients with longer follow-up is needed to ascertain the effect of vaccination on the early natural history of HIV. For power to detect a 30% difference in the rate to reach the composite end point, 140 infected participants from each arm (candidate immunogen and placebo recipients) would be needed. A longer follow-up evaluation of breakthrough infections is also important to assess the potential for immune escape, as described in primate studies of CTL-based simian immunodeficiency virus vaccines [3, 4] .
In conclusion, although candidate canarypox HIV-1 vaccines appear to not alter the natural course of HIV-1 infection in this small number of participants from several canarypox HIV-1 vaccine prime-boost trials, a series of large, randomized, controlled studies in diverse populations will be required to define the effect of preexisting HIV-1 immunity on the long-term sequelae of HIV-1 infection. Our findings underscore the importance of standardizing and providing ART for persons who become infected with HIV while enrolled in vaccine efficacy trials, to enable assessment of the effects of vaccination with CTL-based HIV-1 vaccines on the postinfection natural history of persons after they become infected with HIV, a critical objective in efficacy trials [17] . These observations of individuals who became infected with HIV while enrolled in phase 1 and 2 ALVAC prime-boost trials suggest that the natural history of early HIV infection among vaccinees is similar to that of placebo recipients and historical cohorts. Further evaluation of candidate HIV-1 vaccines designed for gene delivery and induction of HIV-specific CD8 responses, in larger trials, would be useful to define immune correlates of protection or disease progression.
